Study to evaluate the safety and tolerability of <i>Streptococcus salivarius</i> eK12, a genetically modified strain derived from the oral probiotic S. <i>salivarius</i> K12: Results from a randomized, double-blind, placebo-controlled, parallel-group clinical trial.

ABSTRACT: In recent years, genetically engineered probiotics have gained increasing scientific interest owing to their potential applications in human health and nutrition. Streptococcus salivarius K12 is a well-established oral probiotic with an excellent safety record, and a genetically modified derivative, S. salivarius eK12, has been recently developed to enhance its functional properties. The present study evaluated the safety and tolerability of S. salivarius eK12 administered as a dietary supplement in healthy adults. In a randomized, double-blind, placebo-controlled, parallel-group study conducted at the Jam Ghulam Qadir Civil Hospital, Hub, Pakistan (March-August 2025), 29 healthy adults (18-60 years) were assigned to receive S. salivarius eK12 (n = 13) or

SUBMITTER: Di Pierro F 

PROVIDER: S-EPMC12719284 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature